Background: Early invasive carcinoma may be encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. The natural history of these early invasive lesions is unknown. Methods: Pancreatic surgical databases from 4 high-volume centers were queried for IPMNs, with invasive components measuring 20 mm or less. All cases were reviewed by GI gastrointestinal pathologists, and pathologic features were analyzed to identify predictors of recurrence and survival. Results: A total of 70 small IPMN-associated invasive carcinomas ( 20-mm invasion) were identified, comprising 25% of resected IPMN-associated carcinomas (n ¼ 280). Most of these small invasive cancers were multifocal (66%), less than 10 mm in size (73%), and arose in the setting of a main duct IPMN (96%). The most common adenocarcinoma subtypes were tubular (57%) and colloid (29%). Lymph node metastases were present in 19% of cases and 23% were T3 lesions. The overall recurrence rate was 24% (n ¼ 17), and the median time to recurrence was 16 months (range: 4-132 months). Median and 5-year survival rates were 99 months and 59%. Recurrence patterns of invasive disease were local in 35%, distant in 47%, and both in 18%. Lymphatic spread and T3 stage were predictive of recurrence (univariate, P ¼ 0.006), whereas tubular carcinoma type was the most predictive of poor overall survival (multivariate hazard ratio ¼ 3.7, P ¼ 0.04).
I ntraductal papillary mucinous neoplasms (IPMNs) are distinguished from conventional pancreatic ductal adenocarcinoma (PDAC) by their macrocystic appearance, papillary architecture, and mucin-secreting epithelium. However, like PDAC and many extrapancreatic tumors, invasive cancer develops in IPMNs over many years in the context of a dysplasia-to-carcinoma histologic progression. 1, 2 Invasive carcinoma may arise within an IPMN (IPMN-associated carcinoma) and is defined as extension of neoplastic cells through the basement membrane of the involved ducts. IPMNs with associated carcinoma are staged like conventional PDAC using the standard American Joint Committee on Cancer, 7th ed., criteria for pancreatic cancer. 3 IPMNs that harbor foci of invasive carcinoma are at risk for recurrence after resection, in contrast to benign IPMNs that are typically considered curable, although there remains residual risk of additional IPMNs forming in the remnant pancreas in some patients due to a presumed ''field defect.'' [4] [5] [6] [7] Although the risk of recurrence has not been completely characterized, the prognosis is generally believed to be more favorable as compared with conventional PDAC because IPMN-associated carcinomas are frequently diagnosed at an earlier stage. 8, 9 Roughly one-quarter of IPMN-associated carcinomas are detected and resected at the T1 stage ( 20 mm in diameter and confined to the pancreas), and 50% are resected at the T1 or T2 stage (>20 mm, yet still confined to the pancreas). 8 In contrast, 5% of PDACs are resected at the T1 stage and 15% at the T1 or T2 stage. 8, 10 Moreover, some IPMN-associated carcinomas are of the colloid type, which is typically less aggressive than the conventional tubular-type carcinoma. 9 Although IPMN-associated carcinoma and conventional PDAC are considered distinct pathologic entities, it is important to note that they share many clinical, pathologic, and molecular features. For instance, survival after resection of IPMN-associated carcinoma and conventional PDAC is actually similar after adjusting for pathologic features and tumor stage. 8, 9 In addition, the most common subtype of IPMN-associated carcinoma (the tubular or ductal subtype) is indistinguishable from PDAC microscopically. 11 At the molecular level, KRAS mutations are a common feature of both tubular-type IPMNassociated carcinoma and conventional PDAC, 12, 13 although colloidtype invasive carcinomas more commonly contain GNAS mutations (P.J.A., written communication, 2014). Finally, familial pancreatic cancer syndromes (eg, Peutz-Jeghers and Hereditary Breast and Ovarian Cancer syndromes) carry an increased risk for developing both PDAC and IPMN-associated carcinoma, suggesting a common molecular mechanism for tumor initiation. [14] [15] [16] [17] Although IPMNassociated carcinoma and conventional PDAC are clearly separate pathologic entities, it stands to reason that small IPMN-associated carcinomas represent perhaps the best available opportunity to study the biology of early pancreatic cancer.
Beyond biologic insights, a focused analysis of clinical and pathologic outcomes related to small IPMN-associated carcinoma has a more practical purpose. Currently, decisions related to adjuvant therapy of small IPMN-associated carcinoma are rendered in the absence of any reliable data on recurrence risk and long-term survival. Treatment recommendations may be based on experiences with localized and resected conventional ductal adenocarcinoma (PDAC) with a higher T stage that are not truly generalizable to this cohort [18] [19] [20] or even outcome data of early nonpancreatic cancers. For instance, other common cancer types (eg, breast, lung) are typically cured by resection alone when the lesions are under 10 mm in size, and experience with these diseases may perhaps bias oncologists against adjuvant therapy in the setting of small IPMN-associated carcinoma. 21, 22 Studies that specifically profile the clinical outcomes of patients with small IPMNassociated carcinoma may, therefore, inform oncologists on the utility of adjuvant therapy for this diagnosis.
The present study was designed to better understand the clinical and pathologic outcomes in patients with IPMN-associated carcinoma containing foci of invasion of 20 mm or less. Data were collected from 4 high-volume pancreatic cancer programs, and all included cases were rereviewed by expert pancreatic cancer pathologists.
METHODS

Patients
This study was approved by the institutional review boards at the participating centers. Pancreatic surgery databases were queried for all resected IPMN (n ¼ 1122) at Thomas Jefferson University (between years 2006 and 2012, 186 resected IPMN), Massachusetts General Hospital (1993-2012, 434 resected IPMN), Memorial Sloan Kettering Cancer Center (1998-2012, 289 resected IPMN), and the University of Pennsylvania (2007-2013, n ¼ 213). From this cohort, IPMN-associated carcinomas were identified from each institution: 36, 110, 96, and 38, respectively (n ¼ 280, 25% of all resected IPMN). Based on pathology reports and data recorded in institutional databases, the cohort was further refined to include IPMN with invasive foci of 20 mm or less in diameter (small IPMN-associated carcinoma). These included both T1 and T3 lesions according to American Joint Committee on Cancer staging criteria. 3 The size threshold allowed for unambiguous inclusion criteria and was selected because of the criteria used in current TNM (Tumor, Nodes, Metastasis) staging. No T2 lesions were included because these invasive lesions exceed 20 mm, and T3 lesions were included when size criteria were satisfied but the cancer extended beyond the pancreas. Multifocal lesions were categorized according to the largest focus. The size of the benign (or noninvasive) cystic component was recorded but was not a criterion for study inclusion.
Data Collection and Pathology Review
Hematoxylin and eosin stained slides from each of the identified IPMN-associated carcinomas were collected and retrospectively reviewed at each institution by an expert pancreatic cancer pathologist (W.J., O.B, M.M.K., E.E.F.). Cases were excluded after pathologic review if the findings were not conclusive for an IPMN, no invasive component was noted, or invasive foci measured 20 mm or greater. Challenging cases were reviewed under a multi-headed microscopic and a consensus reached by at least 2 pancreatic pathologists from separate participating sites. Specific pathologic features and definitions used in this study are provided in Table 1 .
Clinical data were captured from institutional databases and patient records and included sex, age, adjuvant chemotherapy, adjuvant radiation therapy, time to first recurrence, recurrence pattern, and overall survival. Recurrences were defined as convincing clinical or radiographic evidence of disease. A tissue diagnosis was not required. Sites of recurrence are detailed, and different sites are counted separately when multifocal recurrences were observed. The type of recurrence was categorized as a local-only recurrence (retroperitoneal or surgical bed), distant-only recurrence, or both local and distant recurrence. Attempts were made to capture all cancer recurrences. Records were thoroughly reviewed in an attempt to distinguish true recurrences from metachronous pancreatic cancer whenever possible. Phone calls to patients and families were also utilized to obtain follow-up data in some instances.
Statistical Analysis
Categorical variables were analyzed with x 2 test or logistic regression, whereas comparisons of continuous outcome variables were made using the Mann-Whitney rank sum test. Multivariate logistic regression including statistically significant univariate predictors was used to assess the effects of independent variables on outcomes. Estimates of central tendency are reported as median values. The log rank test and Cox proportional hazards model were used for survival analyses. Statistical significance was accepted for a P value of less than 0.05. Statistics were performed using Stata, version 12.0 (College Station, TX).
RESULTS
Demographic and Perioperative Data
A total of 70 small IPMN-associated carcinomas ( 20 mm invasive component) were identified after pathologic review, which comprised 6.2% of all resected IPMN and 25.0% of all resected IPMN-associated carcinoma at the 4 participating institutions. Clinical data are summarized in Table 2 . The operations included 42 (60.0%) pancreaticoduodenectomies, 14 (20.0%) distal pancreatectomies, 11 (15.7%) total pancreatectomies, and 3 (4.3%) middle pancreatectomies. The patients were evenly split between sexes, and the median age was 69 years (range, 47-91 years). Preoperative CA 19-9 (cancer antigen 19-9) levels were measured in 49 patients, and 13 (26.5%) had elevated values (>37 U/mL). There were 6 patients (8.6%) with CA 19-9 levels above 100 U/mL, and 1 patient had a value above 1000 U/mL (1057 U/mL). These patients all had lesions in the head of the pancreas, and several were believed to have had elevated serum levels due to biliary obstruction.
Pathologic Data
The macroscopic size of the entire lesion measured at resection (including the invasive and intraductal components) ranged from 5 to 150 mm, with a median IPMN size of 30 mm (pathologic data for the cohort are summarized in Table 3 ). Nearly all IPMNs involved the main pancreatic duct (n ¼ 67, 95.7%), whereas only 3 (4.3%) were entirely limited to a side-branch duct. The distribution of non-IPMNassociated carcinoma epithelial subtypes was as follows: 32 (45.7%) Fig. 1 , available at http://links.lww.com/SLA/A798).
The size of the invasive component was 20 mm or less for all cases in the study based on inclusion criteria but less than 10 mm in 73% of patients; the median size of the invasive component in the series was 5 mm (range, 0.5-20 mm). The cohort was subcategorized by size of the invasive component at 5-mm intervals (0-4 mm, 5-9 mm, 10-14 mm, and 15-20 mm) with the following distribution: 35 (50.0%), 16 (22.9%), 7 (10.0%), and 12 (17.1%), respectively. Histologic subtypes of invasive cancer included tubular (n ¼ 40, 57.1%), colloid (n ¼ 20, 28.6%), oncocytic (n ¼ 7, 10.0%), signet ring (n ¼ 1, 1.4%), and mixed (n ¼ 2, 2.9%) ( Fig. 1A-H ). Multiple foci of invasive disease were observed in two-thirds of the cohort.
Regional lymph node metastases were identified in 13 (18.8%) specimens. Five patients had regional lymph node metastases identified in more than 1 node (2 positive nodes in 1 patient, 4 positive nodes in 2 patients, and 5 positive nodes in 2 patients). Microscopic vessel invasion was observed in just 2 patients with cancer (2.9%), microscopic lymphatic invasion in 10 patients (14.3%), and microscopic perineural invasion in 14 patients (19.0%). The invasive component was well differentiated in 22 patients (31.9%), moderately differentiated in 39 (56.5%), and poorly differentiated in 8 patients (11.6%).
Neoplastic cells were observed at a resection margin in 17 (24.3%) cases. Specifically, the findings were noted to be PanIN lesions at the margin in 6 (8.6%) patients, IPMN in 8 patients (11.4%), and invasive cancer in 3 patients (4.3%). The degree of dysplasia (PanIN and IPMN lesions grouped together) at the margin was low grade in 2 patients (2.9%), intermediate grade in 3 patients (4.3%), and high grade in 9 patients (12.9%).
Recurrence and Survival
Recurrent cancer was identified in 17 patients (24.3%), and sites of recurrence included the retroperitoneum (including the surgical bed and/or pancreatic remnant), peritoneum, liver, lung, and spleen (Table 4 ). There were 4 patients who had recurrence in the remnant pancreas, raising the possibility that the presumed recurrence was a metachronous (ie, separate primary) pancreatic cancer in these cases. Based on careful review of patient records, one of these cases was particularly suspicious for a second primary (as opposed to a true intraductal recurrence of the original cancer), because the disease-free interval was more than 10 years, and the original IPMNassociated carcinoma was a colloid carcinoma without lymph node spread (ie, presumably a low-risk lesion). In contrast, the other 3 patients experienced early recurrences (7, 12 , and 14 months) and had high-risk IPMN-associated carcinomas found within the original pancreatic resection specimen. The first patient had perineural invasion and a single regional lymph node metastasis at first resection, the second patient had a poorly differentiated invasive focus with perineural and lymphatic invasion, and the third patient had carcinoma in situ at the resection margin.
Approximately one-third of the patients who had a recurrence experienced a local recurrence only, whereas two-thirds experienced a distant recurrence (either in isolation or in association with a local recurrence). In this small cohort, there was no specific pathologic feature that associated with a particular recurrence pattern. The median time to recurrence was 16.2 months (range, 4-132 months) in the cohort. The time of first recurrence was greater than 4 years after resection in 6 patients ($1/3 of recurrences).
The overall median follow-up in the entire cohort was 26.2 months (range, 0.2-179 months). There were 22 deaths (31.4%) during the study period, whereas 48 (68.6%) patients were still alive at last follow-up. Among the living patients, the median length of follow-up was 28.7 months. For much of the living cohort, the follow-up was short; overall survival was censored within 10 months in 12.9% of this subgroup and within 5 months in 8.6%. The median estimated survival in the whole cohort of small IPMN-associated carcinomas was 99 months, the 1-year-survival was 90%, and the 5year survival was 59% ( Fig. 2A) . In a subgroup analysis of the 2 most common adenocarcinoma subtypes, patients with colloid carcinoma had superior overall survival to those with tubular adenocarcinoma The provided percentages are in reference to patients who had a recurrence. yPercentages add up to greater than 100%, as some patients had recurrence at multiple sites. ( Fig. 2B, 2- year survival of 95% and 62%, respectively, P ¼ 0.02). Adjuvant chemotherapy was given to a minority of patients (n ¼ 15, 21.4%), with 11 of these patients additionally receiving chemoradiation (15.7% of the cohort).
Risk Factors for Recurrence and Survival
Clinicopathologic features were analyzed to identify risk factors for cancer recurrence. The univariate analysis is presented in Supplemental Digital Content Table 1 , available at http://links. lww.com/SLA/A799. The presence of regional lymph node metastases (53.9% recurrence rate vs 17.5% recurrence rate in the absence of nodal metastases, x 2 P ¼ 0.006), microscopic lymphatic invasion (50.0% vs 20.0%, P ¼ 0.04), and T3 stage (50.0% vs 16.7%, P ¼ 0.006) were statistically significant univariate risk factors for recurrence. Notably, adjuvant chemotherapy use was not associated with recurrence risk (40.0% recurrence with chemotherapy vs 20.0% without chemotherapy, P ¼ 0.11). There were no predictors of recurrence in a multivariate logistic regression model including these univariate risk factors (positive nodes, T3 stage, lymphatic invasion). However, this is very likely related to the strong overlapping variance in this small data set among the independent significant univariate variables. Both T3 stage (7.4% T1-stage cancers had regional lymph node metastases vs 56.3% T3-stage) and lymphatic invasion (10.0% without lymphatic invasion vs 70.0% with lymphatic invasion, P < 0.001) were highly associated with regional lymph node metastases.
Recurrence risk was analyzed in greater detail across various subgroups to determine whether clusters of pathologic features may be identified with an especially low recurrence risk, such that patients meeting specified criteria may reliably be considered to be cured by resection. As indicated previously, size was not predictive of recurrence in this cohort. IPMN-associated carcinoma with invasive foci of less than 5 mm in fact had a statistically similar recurrence rate (17.1%, 6 out of 35) to larger invasive lesions (31.4%, P ¼ 0.2, Table 5 ). Regional lymph node involvement was also observed in the smallest cancers (0-to 4-mm diameter, 3 of 35, 8.6%), providing further evidence of the metastatic potential of early IPMN-associated carcinoma. Notably, the rate of lymph node spread was directly related to invasive component size (linear regression, slope coefficient 10.9, P ¼ 0.002). Importantly, even the invasive foci in the smallest size range (foci <5 mm) and without apparent lymph node spread still carried a substantial recurrence risk (12.4%, 4 of 32). Colloid carcinomas represent a particularly favorable subtype of IPMN-associated carcinoma, 9 and in the present series, none of the cases in this subgroup (n ¼ 20) exhibited regional lymph node spread. Two recurrences were noted in this subgroup (10%, 2 out of 20), although in 1 instance, the recurrence occurred after a very long disease-free interval (10 years, previously highlighted) and most likely represented a metachronous PDAC primary, as already mentioned.
In the absence of adverse univariate risk factors for recurrence (regional lymph node metastases, lymphatic invasion, T3-stage), IPMN-associated carcinomas still had a recurrence rate of 12.5% (6 recurrences of 48 cases without these three risk factors). Tubular carcinoma with this cluster of favorable pathologic features had an 8.3% recurrence risk (2 of 24), whereas colloid carcinoma meeting these criteria had a recurrence rate of 5.9% (1 of 17). Again, the single recurrence in the latter group occurred in the previously described patient with a presumed metachronous primary lesion, suggesting that this group of patients may indeed have a uniquely favorable biology.
Pathologic features were also evaluated as predictors of overall survival. In univariate analyses, tubular adenocarcinoma (vs colloid carcinoma, P ¼ 0.02), intermediate-grade dysplasia (or greater) at the transected pancreatic margin (P ¼ 0.004), and T3 stage (0.03) were associated with a poor outcome. In a multivariate Cox proportional hazards model including these 3 variables, tubular adenocarcinoma (hazards ratio ¼ 3.7, P ¼ 0.04) remained statistically significant. In summary, lymphatic spread of disease and T3 stage were predictive of recurrence, whereas tubular subtype (vs, colloid) was most predictive of worse overall survival.
DISCUSSION
In the modern era of high-resolution cross-sectional imaging, IPMNs are encountered with increased frequency and are often asymptomatic. A study of more than 2000 computed tomographic scans obtained in the general population for a multitude of indications identified asymptomatic pancreatic cysts in 2% of cases, and a large number of these lesions were likely IPMNs. 23 Most of these incidentally discovered that IPMNs are indolent and unlikely to be clinically relevant during an individual's lifetime. However, a minority will grow and transform over time into lethal cancers if left untreated. Recent surgical series suggest that 5% to 10% of pancreatic resections at high-volume centers are now performed for IPMNs. 20 There has been a strong focus in the surgical literature toward understanding which IPMNs are at highest risk for malignant transformation and should be resected at a curable stage. International Consensus Guidelines have been recently published on this subject 24, 25 and suggest that IPMNs be resected if the cyst causes symptoms, contains mural nodules, or involves the main pancreatic duct, after considering the age and performance status of the patient. 24 IPMNs that measure more than 3 cm on cross-sectional imaging without these high-risk stigmata may also be considered for resection, particularly in younger patients. 24 In light of the growing number of detected IPMNs, highvolume centers are encountering a growing number of lesions that have small foci of invasive cancer. Importantly, these early IPMNassociated carcinomas provide a unique lens into the natural history and biology of pancreatic cancer. To our knowledge, outcome studies that focus on small IPMN-associated carcinomas have been limited to a handful of small studies from East Asia. [26] [27] [28] In 1 study by Nara et al, 27 104 cases of resected IPMNs were analyzed over a 20-year period. There were 51 IPMN-associated carcinomas that were subgrouped into 4 pathologic categories: (1) ''infiltrative growth,'' (2) ''mucous rupture,'' (3) ''expansile growth,'' and (4) ''intraabdominal rupture.'' Criteria for ''minimal invasion'' were separately applied to each of the 4 phenotypes, and size of the invasive 29 In the overall group of 26 ''minimally invasive'' IPMN-associated carcinomas, just 2 (7.7%) recurrences were reported. None of the minimally invasive IPMNassociated carcinomas spread to regional lymph nodes in the study, and the 10-year disease-specific survival in these patients was 100%.
When size was used to stratify patients, 23 IPMN-associated carcinomas harbored an invasive component under 20 mm; there were 5 recurrences in this group, yielding a comparable recurrence rate to the findings reported herein. A South Korean study using the aforementioned Japanese criteria for minimal invasion reported 2 recurrences out of 24 cases (8.3%), 28 whereas a separate Japanese study identified 2 recurrences in 5 patients with minimally invasive IPMN-associated carcinoma. 26 The current multi-institutional study of 70 patients with small IPMN-associated carcinoma represents the largest study on the subject to date. The cohort entirely comprised IPMN involving the main duct on pathologic review, suggesting that small IPMNassociated carcinomas that exclusively involve side branch ducts are extremely rare. The data reveal a recurrence rate after resection for small IPMN-associated carcinoma ( 20-mm invasive component) of 24.3% at a median follow-up of just more than 2 years (26.1 months). Regional lymph node metastases, microscopic lymphatic invasion, and T3 stage were identified as unadjusted predictors of recurrence. Importantly, tubular-type carcinomas were still at risk for recurrence, even when these 3 adverse features were absent. In contrast, the findings from this study suggest that small colloid carcinomas ( 20-mm invasive component) lacking these 3 risk factors are likely to be cured by resection. Because of strong interdependence of the 3 univariate predictor variables of recurrence, none of the univariate risk factors retained statistical significance in the multivariate regression model.
It is worth highlighting a counterintuitive (statistically insignificant) trend toward increased recurrence observed with adjuvant chemotherapy use, which was likely attributable to the selection bias of high risk cancers in the chemotherapy group. For instance, patients undergoing adjuvant chemotherapy had a higher rate of lymph node metastases (46.7% vs 10.9%, P ¼ 0.002). Finally, tubular adenocarcinoma subtype was the single adverse prognostic factor for survival in a multivariate Cox model. This adverse risk factor failed to predict recurrence (P ¼ 0.12), possibly related to the underpowered nature of the small sample size.
There are several unique aspects to this study worth highlighting. First, data from 4 separate high-volume institutions were collated to generate a modest sample size necessary for meaningful analyses. In addition, inclusion of patients from multiple data sets reduces potential institutional biases present in many published series (such as referral patterns, quality of follow-up in institutional databases, etc). Importantly, recurrence rates at the 4 participating centers were consistent and ranged between 20% and 33% (P ¼ 0.9). Every case included in the present analysis was reexamined by an expert pancreatic cancer pathologist. All challenging cases from each site were reviewed by at least 1 additional pancreatic pathologist from a separate participating institution, and a consensus was reached between pathologists regarding the pathologic features in question. The active involvement of pancreatic pathologists from each site is a particular strength of the study. Numerous conversations and e-mails were performed by pathologists to ensure the integrity and consistency of the pathologic review and data analysis.
The relative small sample size and retrospective aspect of this study are clear limitations that should be considered when interpreting these data. However, it is likely that the retrospective nature of the data collection may in fact bias the results toward an underestimation of the true recurrence rate for small IPMN-associated carcinoma. There are several lines of evidence that support this interpretation. First, the long-term follow-up in the study was incomplete. The median time to recurrence in the cohort was 16 months, yet 25% of recurrences occurred beyond 5 years. The median follow-up period for living patients was just more than 2 years in the study, suggesting that roughly one-third of recurrences have yet to manifest clinically or are unknown to the study investigators. Second, there was uncertainty regarding the cause of death for many of the patients in the study. A total of 22 deaths were recorded (31.9% of the cohort), yet only 9 deaths (40.9% of deaths) occurred in patients with documented disease recurrence. It is quite conceivable, and in fact probable, that at least some of the remaining deaths (13 of 22, 59.1%) are attributable to cancer recurrence, unbeknownst to the study investigators.
An additional limitation of this retrospective study relates to the challenge of distinguishing true recurrences from metachronous pancreatic cancer (ie, a second independent pancreatic cancer). With the exception of 1 instance highlighted previously (a ''recurrence'' 10 years after a resection of a 5-mm colloid carcinoma), all of the recurrences in the present series were presumed to represent true recurrences after a rigorous review of electronic records. Nevertheless, we cannot definitively make this claim without genomic sequencing and genotyping respective tumors (ie, comparing the molecular profile of the recurrence with the corresponding resected primary 2, 30 ). We, therefore, did not exclude cases from this study when the distinction was unclear. The prior literature provides some support that questionable cases, particularly ones that involve the pancreatic remnant, more likely represent true intraductal recurrences than second primary cancers. For instance, the incidence of PDAC after resection of benign IPMN disease, or in patients with low-risk IPMN, followed by surveillance imaging, is reportedly much lower (4%) than the recurrence rate observed in this study (24%). [4] [5] [6] In addition, metachronous PDAC in patients with benign IPMN disease typically occurs after a longer disease-free interval than the time-to-recurrence reported in this study. Only 15% of metachronous PDAC occur by 15 months as reported in the literature, 4, 5 whereas half of the patients in this study had recurrence by that same time point (suggesting invasive cancer recurrence). Other limitations of the study include difficulty in determining which factors led surgeons to recommend resection, an unclear understanding of why patients did not receive adjuvant therapy, and a lack of understanding of the natural history of unresected small IPMN-associated carcinoma.
The very real and substantial recurrence risk of small IPMNassociated carcinoma runs counter to experiences with other common solid tumors and may reflect intrinsic biologic differences between pancreatic adenocarcinoma and these other solid tumor types. For instance, breast cancers less than 2 cm have a relative 5year survival rate in excess of 95% (as compared with 59% in the present cohort). 22 Similar findings have been reported for non-small cell lung cancer 21 ; in the absence of lymph node metastases, resection of these small, non-pancreatic cancers is typically curative. 21, 31 Although the recurrence rate reported in the present study may be surprising in the context of these other tumor types, the data are actually consistent with recent molecular and preclinical studies of pancreatic cancer. Mounting evidence suggests that malignant pancreatic cells disseminate at a very early stage. Yachida et al 2 performed genomic sequencing in paired primary and metastatic PDAC from 7 individuals enrolled in a rapid autopsy program. Using a ''molecular clock'' concept based on passenger mutation rates, the authors determined that metastatic subclones emerge in primary pancreatic tumors an average of 2.7 years (or 31 months) before the death of the patient. Because patients with localized and resectable PDAC typically present clinically 18 months before this terminal outcome (ie, the median survival after resection), 20 one can logically infer that micrometastases frequently predate a patient's operative resection date. This inference is supported by clinical experience, because more than 90% of patients with PDAC ultimately have recurrence after a complete resection for PDAC. 20 Considering a typical cancer doubling time of roughly 3 months, 32 one can even extrapolate backward from these data to estimate the size of an invasive lesion capable of metastatic spread. Roughly 3 to 4 doubling times occur over the 13 months that separate the calculated emergence of metastatic clones and resection of a 3-cm PDAC (the median size at resection). 20 A ''back of the envelope'' calculation suggests then that metastases occur in patients harboring invasive carcinoma foci measuring just 2 to 4 mm in size.
In an experimental mouse study, Rhim et al 33 used a sophisticated cell lineage-labeling transgenic mouse to track pancreatic cancer cells geographically. In this mouse model, all preinvasive pancreas cells containing mutant KRAS and TP53 genes expressed a gene encoding a fluorescent reporter protein, enabling investigators to trace premalignant cells throughout the animal. Fluorescently labeled cells were detected in the blood and liver tissue in mice that harbored only noninvasive PanIN lesions in their pancreas by histologic review. In this model, cells considered as ''noninvasive'' actually demonstrated metastatic potential, suggesting that conventional histologic classification schemes are inconsistent with disease biology in this context.
CONCLUSIONS
This study revealed a recurrence risk of 24.3% for resected small IPMN-associated carcinoma ( 20-mm invasive component) at a median follow-up interval of 26.2 months. Because of incomplete follow-up and unknown causes of death in several patients, the true recurrence rate of these early invasive lesions may in fact be higher, which has important implications on the postoperative management and surveillance of patients with small IPMN-associated carcinoma. In light of the real and substantial recurrence risk observed in this cohort of patients, adjuvant chemotherapy (with or without radiation) should be considered and may be the preferred approach in younger patients with a good performance status, particularly to treat the tubular (ductal) subtype. These patients should be followed postoperatively with close surveillance plans, similar to patients with resected conventional PDAC (eg, imaging, physical examination, and serum tumor markers every 3-6 months for 2 years, then annually or semiannually). 34 These data also suggest that effective early detection strategies for pancreatic cancer must achieve detection capabilities that are superior to available technologies to identify invasive lesions in the subcentimeter range before systemic dissemination. Finally, for IPMN-associated carcinomas, the size of the invasive component should be indicated on pathology reports separately from the overall cyst size when possible because tumor staging is based on the extent of invasive disease.
